64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial
Authors:
- Keith WongKWKeith Wong
- Gemma Sheehan-DareGSGemma Sheehan-Dare
- Andrew NguyenANAndrew Nguyen
- Bao HoBHBao Ho
- Victor LiuVLVictor Liu
- Jonathan LeeJLJonathan Lee
- Lauren BrownLBLauren Brown
- Rachel DearRDRachel Dear
- Lyn ChanLCLyn Chan
- Shikha SharmaSSShikha Sharma
- Alessandra MalarodaAMAlessandra Malaroda
- Isabelle SmithISIsabelle Smith
Open Access
- 22 June 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (7) , 772
Abstract
Breast cancers are most frequently oestrogen receptor (ER) and progesterone receptor (PR) positive and [18F]Fluorodeoxyglucose PET-CT (FDG) has lower sensitivity for these subtypes. The gastrin-releasing peptide receptor (GRPR) is overexpressed in ER+/PR+ breast cancers. This study assessed the safety and potential of [64Cu]Cu-Sarcophagine (SAR)-Bombesin PET/CT (BBN) in re-staging metastatic ER+/PR+/human epidermal growth-factor-2-negative (HER2-) breast cancer. Seven patients with metastatic ER+/PR+/HER2- breast cancer undergoing staging underwent [64Cu]Cu-SAR-BBN PET-CT. Bloods, vital signs and electrocardiogram, blood tracer-clearance and dosimetry were undertaken. GRPR status was assessed in available metastatic biopsy samples. Staging with conventional imaging ([18F]FDG, bone scan and diagnostic CT) was within 3 weeks of [64Cu]Cu-SAR-BBN PET/CT. PET scans were assessed visually and quantitatively. Seven patients underwent imaging. One of the seven had de-novo metastatic breast cancer and six of the seven recurrent metastatic disease. Two of the seven had lobular subtype. No adverse events were reported. All seven patients were positive on conventional imaging (six of seven on FDG). [64Cu]Cu-SAR-BBN imaging was positive in five of the seven. Both [64Cu]Cu-SAR-BBN-negative patients had disease identified on [18F]FDG. One patient was [64Cu]Cu-SAR-BBN positive/[18F]FDG negative. Four of seven patients were [64Cu]Cu-SAR-BBN positive/[18F]FDG positive. In these four, mean SUVmax was higher for [64Cu]Cu-SAR-BBN than [18F]FDG (SUVmax 15 vs. 12). In the classical lobular subtype (two of seven), [64Cu]Cu-SAR-BBN was more avid compared to [18F]FDG (SUVmax 20 vs. 11, and 20 vs. 64Cu]Cu-SAR-BBN to be 1.9 mSv. [64Cu]Cu-SAR-BBN PET/CT appears safe and may have diagnostic value in metastatic ER+/PR+/HER2- breast cancer, particularly the lobular subtype. Further evaluation is warranted.Keywords
Funding Information
- Clarity Pharmaceuticals
This publication has 26 references indexed in Scilit:
- Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate CancerMolecular Pharmaceutics, 2015
- Effectiveness of Breast MRI and18F-FDG PET/CT for the Preoperative Staging of Invasive Lobular Carcinoma versus Ductal CarcinomaJournal of Breast Cancer, 2015
- Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Use of Normal Tissue Complication Probability Models in the ClinicInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Radiation-Associated Kidney InjuryInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Gastrin-Releasing Peptide Receptor Imaging in Human Breast Carcinoma Versus ImmunohistochemistryJournal of Nuclear Medicine, 2008
- Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parametersCancer, 2007
- MicroPET Imaging of Breast Cancer Using Radiolabeled Bombesin Analogs Targeting the Gastrin-releasing Peptide ReceptorBreast Cancer Research and Treatment, 2006
- Hematologic Toxicity in Radioimmunotherapy: Dose-Response Relationships for I-131 Labeled Antibody TherapyCancer Biotherapy and Radiopharmaceuticals, 2002
- Gastrin-Releasing Peptide Receptors in Non-Neoplastic and Neoplastic Human BreastThe American Journal of Pathology, 1999